jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Fibroadenoma Biopsy - XL

Biopsy
image

Report in 288Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Breast lump biopsy.

₹888₹1,269

30% OFF

Fibroadenoma Biopsy - XL: Comprehensive Medical Test Guide

  • Why is it done?
    • Definitive diagnosis of breast fibroadenomas using large-bore needle biopsy technique (XL designation indicates extra-large specimen collection)
    • Differentiate benign fibroadenomas from phyllodes tumors or other malignant breast lesions
    • Evaluate palpable breast masses or lesions identified on mammography, ultrasound, or MRI
    • Provide tissue specimens for histopathological examination and immunohistochemical analysis
    • Exclude malignancy when imaging characteristics are indeterminate or concerning (BI-RADS 4-5)
    • Typically performed when fine-needle aspiration (FNA) or core needle biopsy results are inconclusive or when larger tissue samples are needed
  • Normal Range
    • Normal Result: Benign fibroadenoma with characteristic histology (epithelial and stromal components without malignancy)
    • Histopathological Features of Benign Fibroadenoma: • Well-circumscribed lesion • Mixed epithelial and stromal components • No cellular atypia (mild to moderate atypia may be present) • No increased mitotic activity • Absent necrosis • No lymphocytic infiltration or inflammation
    • Interpretation Scale: • Benign (B2): Fibroadenoma - Normal finding • Atypical (B3): Requires follow-up imaging and possible re-biopsy • Suspicious (B4): Requires diagnostic excision or repeat biopsy • Malignant (B5): Requires surgical intervention
  • Interpretation
    • Benign Fibroadenoma (B2 Classification): Confirms diagnosis of common benign breast tumor; no malignant potential; routine surveillance recommended; surgical removal optional based on symptoms or cosmetic concerns
    • Complex Fibroadenoma: Contains cysts, calcifications, or other features; still benign but may warrant closer surveillance or imaging follow-up every 6-12 months
    • Phyllodes Tumor (Borderline/Low-grade): Shows increased stromal cellularity and mitotic activity; rare but requires surgical excision with adequate margins; recurrence risk is low to moderate
    • Phyllodes Tumor (High-grade/Malignant): Demonstrates significant atypia, high mitotic rate, and stromal overgrowth; requires wide surgical excision and oncology consultation; significant risk of recurrence and metastasis
    • Atypical Ductal Hyperplasia (ADH) - B3: Associated findings requiring 6-month imaging follow-up and consideration of diagnostic excision; increased breast cancer risk
    • Factors Affecting Interpretation: • Patient age and hormonal status • Lesion size and imaging characteristics • Rate of growth on follow-up imaging • Adequacy of tissue sampling • Immunohistochemical staining results • Clinical presentation and symptoms
  • Associated Organs
    • Primary Organ System: Mammary gland (breast tissue); involves epithelial and stromal components of the breast
    • Common Associated Conditions - Benign: • Simple fibroadenoma • Complex fibroadenoma (with cysts or calcifications) • Adenosis • Fibrocystic changes • Papilloma
    • Potentially Malignant Conditions to Exclude: • Phyllodes tumors (benign, borderline, or malignant) • Invasive ductal carcinoma • Invasive lobular carcinoma • Ductal carcinoma in situ (DCIS) • Atypical ductal hyperplasia (ADH) • Atypical lobular hyperplasia (ALH)
    • Potential Complications/Risks of Abnormal Results: • Need for surgical intervention (excision of phyllodes tumors) • Increased surveillance requirements • Psychological impact of borderline or atypical findings • Risk of recurrence if malignancy detected • Potential systemic treatment requirement • Increased lifetime breast cancer risk with ADH findings
    • Biopsy-Related Complications (Rare): • Bleeding or hematoma formation • Infection • Scarring • Nerve injury • Pneumothorax (with apical lesions)
  • Follow-up Tests
    • If Benign Fibroadenoma Confirmed: • Baseline mammography or ultrasound if not recently performed • Routine clinical breast examination annually • Standard screening mammography per age-appropriate guidelines • Optional imaging follow-up at 6-12 months if lesion large or concerning features
    • If Complex Fibroadenoma or Borderline Features: • Breast ultrasound at 6 months • Follow-up mammography at 6-12 months • MRI breast if further characterization needed • Consider diagnostic excision if imaging changes or growth noted
    • If Phyllodes Tumor (Any Grade): • Surgical consultation for wide local excision or mastectomy • Oncology consultation, particularly for high-grade lesions • Chest imaging (CT chest) for high-grade tumors to assess for metastases • Enhanced surveillance imaging post-operatively (every 3-6 months initially)
    • If Atypical Findings (ADH/ALH) Present - B3: • Diagnostic excisional biopsy recommended • Breast imaging follow-up at 6 months, then annually • High-risk breast cancer screening protocol • Genetic counseling/testing if multiple atypical lesions • Consider chemoprevention (tamoxifen) evaluation
    • If Malignancy Detected - B5: • Surgical oncology consultation • Staging studies (breast MRI, chest imaging, labs) • Genetic testing consideration (BRCA1/2) • Hormone receptor and HER2 testing • Treatment planning (surgery, radiation, chemotherapy, hormonal therapy)
    • Complementary Diagnostic Tests: • Immunohistochemistry (IHC) for estrogen/progesterone receptor status • HER2 testing • Ki-67 proliferation index • ER/PR testing for therapeutic decision-making • Molecular subtyping if malignancy confirmed
  • Fasting Required?
    • Fasting Required: NO - This is a tissue biopsy procedure; fasting is not necessary
    • Pre-Biopsy Preparation: • NPO (nothing by mouth) not required • Eat and drink normally before procedure • Arrive 15-30 minutes early for check-in
    • Medications to Avoid/Hold: • Anticoagulants (warfarin, dabigatran, rivaroxaban) - hold 3-5 days prior with physician approval • Antiplatelet agents (aspirin) - hold 3-7 days prior if possible • NSAIDs (ibuprofen, naproxen) - hold 5-7 days prior • Herbal anticoagulants (ginkgo, ginseng, garlic) - hold 1 week prior • Verify specific instructions with interventional radiologist or surgeon
    • Special Instructions: • Wear comfortable, loose-fitting clothing that allows easy breast access • Bring insurance card and photo ID • Avoid wearing deodorant, perfume, or powder on breast area • Mark the biopsy site (if palpable mass) with indelible marker on day of procedure • Arrange transportation if conscious sedation is used • Bring a list of current medications for review
    • Anesthesia: Local anesthesia (lidocaine) administered at biopsy site; rarely requires sedation unless multiple biopsies planned
    • Post-Biopsy Instructions: • Resume normal eating and drinking immediately • Apply ice pack for 15-20 minutes every hour for first 24 hours • Take over-the-counter acetaminophen for discomfort (avoid NSAIDs for 24 hours) • Wear supportive bra for 2-3 days • Resume normal activities, but avoid strenuous exercise or heavy lifting for 1 week • Keep biopsy site clean and dry • Watch for signs of infection (increased pain, redness, drainage)

How our test process works!

customers
customers